UBS AM
AVXL icon

UBS AM’s Anavex Life Sciences AVXL Stock Holding History

UBS AM’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$575 Hold
222
– – ﹤0.01% 3649
2026
Q1 		$682 Sell
222
-161,902
-100% -$701K ﹤0.01% 3708
2025
Q4 		$577K Buy
162,124
+71
+0% +$435 ﹤0.01% 2297
2025
Q3 		$1.44M Sell
162,053
-65,688
-29% -$666K ﹤0.01% 1877
2025
Q2 		$2.1M Buy
227,741
+129,107
+131% +$1.1M ﹤0.01% 2115
2025
Q1 		$846K Buy
+98,634
New +$931K ﹤0.01% 2373
2024
Q2 		– Sell
-96,924
Closed -$493K – 2807
2024
Q1 		$493K Hold
96,924
– – ﹤0.01% 2289
2023
Q4 		$902K Hold
96,924
– – ﹤0.01% 2087
2023
Q3 		$635K Hold
96,924
– – ﹤0.01% 2186
2023
Q2 		$831K Hold
96,924
– – ﹤0.01% 2087
2023
Q1 		$831K Buy
+96,924
New +$967K ﹤0.01% 2087
2022
Q4 		– Sell
-96,244
Closed -$993K – 2580
2022
Q3 		$993K Hold
96,244
– – ﹤0.01% 1975
2022
Q2 		$963K Buy
96,244
+31,859
+49% +$302K ﹤0.01% 1987
2022
Q1 		$793K Hold
64,385
– – ﹤0.01% 2260
2021
Q4 		$1.12M Sell
64,385
-4,366
-6% -$83K ﹤0.01% 2154
2021
Q3 		$1.23M Buy
68,751
+567
+0.8% +$11.3K ﹤0.01% 2051
2021
Q2 		$1.56M Buy
+68,184
New +$1.01M ﹤0.01% 1970

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS AM's AVXL Position: Q2 2026 in Review

UBS AM held its Anavex Life Sciences (AVXL) position steady in Q2 2026 at 222 shares worth $575. The position accounts for ﹤0.01% of the portfolio, ranked #3649.

UBS AM first reported a position in AVXL in Q2 2021 and has held it in 17 quarters since. The position peaked at $2.1M in Q2 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • UBS AM held 222 shares of Anavex Life Sciences worth $575 as of Q2 2026.
  • UBS AM left its Anavex Life Sciences share count unchanged in Q2 2026.
  • Anavex Life Sciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3649 holding.
  • UBS AM first reported a position in Anavex Life Sciences in Q2 2021 and has held it in 17 quarters since.
  • UBS AM's Anavex Life Sciences position peaked at $2.1M in Q2 2025.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.